This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Glossary
- EA2=
- episodic ataxia type 2;
- FHM1=
- familial hemiplegic migraine type 1;
- HVA=
- high voltage-activated;
- LVA=
- low voltage-activated;
- PD=
- Parkinson disease;
- SCA6=
- spinocerebellar ataxia type 6;
- SNc=
- substantia nigra pars compacta;
- SW=
- spike-and-wave.
Voltage-gated calcium (Ca2+) channels are a major source of Ca2+ influx and have a critical role in Ca2+ signaling in all cells. The nervous system expresses a number of different types of voltage-gated Ca2+ channels, each with unique cellular and subcellular distributions and specific physiologic functions. Studies in vitro or in knockout mice have provided insight into the function of the different types of voltage-gated Ca2+ channels. L-Type channels regulate neuronal excitability and gene expression; P/Q and N channels trigger neurotransmitter release, and T-type channels support neuronal rhythmic burst firing. Evidence from natural mutants, knockout mice, and human genetic disorders indicate a fundamental role of some voltage-gated Ca2+ channels in a wide variety of neurologic disorders, including seizures, ataxia, and neuropathic pain. There are several excellent reviews on the structural features, regulation, and function of the different types of voltage-gated Ca2+ channels1–5 and their implication in neurologic diseases.6–10 Only few salient concepts are emphasized here.
SUBTYPES AND STRUCTURE OF VOLTAGE-GATED CALCIUM CHANNELS
Classification.
Voltage-gated Ca2+ channels have been classified into 2 major categories on the basis of their threshold of activation by depolarization, high voltage-activated (HVA) channels, and low voltage-activated (LVA) channels (table 1). The HVA channels can be further subdivided, based on pharmacologic and biophysical characteristics, into L-, N-, P/Q-, and R types.1,2
- In this window
- In a new window
Table 1 Main features of voltage-gated calcium channels
Structure.
All voltage-gated Ca2+ channels contain a pore-forming α1 subunit that determines their main biophysical and pharmacologic properties. There are 3 major families of α1 subunits—Cav1, Cav2, and Cav3—each consisting of several subtypes (table 1). The Cav1 family encodes L-type channels; the Cav2 family includes 3 different isoforms that encode P/Q- (Cav2.1), N- (Cav2.2), and R- (Cav2.3) …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
- Neuronal voltage-gated calcium channels: Brief overview of their function and clinical implications
- Reply from the author
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen